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Peroxisome proliferator-activated receptor (PPAR)-α, a member of a large nuclear receptor superfamily, plays a major role in
the regulation of lipid metabolism. Recently, PPARα activation has been shown to confer additional beneﬁts on endothelial
function, kidney function, and anti-inﬂammation, suggesting that PPARα agonists may be good candidates for treating acute
renal failure. In clinical application, PPAR-α activators, such as hypolipidemic drugs in ﬁbric acid class, were proven to have
therapeutic eﬀects on metabolic syndrome and cardiovascular disease. This paper focuses on signaling pathways, ligand selectivity,
and physio-pathological roles of PPARα in kidney diseases and the therapeutic utility of PPARα modulators in the treatment of
diabetesandinﬂammation-inducednephropathy.ImplicationofnewandmorepotentPPAR-αactivatorscouldprovideimportant
insights into the overall beneﬁts of activating PPAR-α clinically for the treatment of dyslipidemia and the prevention of diabetic or
inﬂammation-induced nephropathy in the future.
1. PeroxisomeProliferator-ActivatedReceptors
Peroxisome proliferator-activated receptors (PPARs) are
nuclear hormone receptors, that is, ligand-dependent intra-
cellularproteins that stimulate transcription of speciﬁc genes
by binding to speciﬁc DNA sequences. When activated
by appropriate ligand binding, their transcription factors
aﬀect development and metabolism. There are three PPAR
subtypes, products of the distinct genes commonly desig-
nated as PPARα,P P A R γ,a n dP P A R β/δ,o rm e r e l yδ [1].
The PPARs usually heterodimerize with another nuclear
receptor, the 9-cis-retinoic acid receptor (RXR), forming a
complex that interacts with speciﬁc DNA-response elements
within the promoter regions of the target genes. Ligand
bindingcanactivatethisheterodimercomplexwhichrecruits
transcription coactivators and regulates the transcription of
genes involved in the regulation of lipid and carbohydrate
metabolism [1]. Like several other nuclear hormone recep-
tors, it heterodimerizes with RXR to form a transcriptionally
competent complex [2].
2. TissueExpressionofPPARsandTheirRolein
Renal Injury
PPARα,P P A R β/δ,a n dP P A R γ are diﬀerentially expressed in
various tissues [3–5]. In general, PPARα is highly expressed
in tissues that possess high mitochondrial and β-oxidation
activity, including the liver, renal cortex, intestinal mucosa,
and heart, with lower expression in several other tissues.
PPARγ is highly enriched in adipose tissue, while lower
expression levels are reported in the urinary bladder, intes-
tine, kidney, spleen, adrenal, heart, liver, lung, brain, and
vasculature.UnlikePPARαandPPARγ,low-levelexpressions
of PPARβ/δ is ubiquitously found in almost every tissue
examined. In the kidney, PPARα is abundantly expressed
in the proximal tubules and the medullary thick ascend-
ing limbs with much lower expression in the glomerular
mesangial cells [5, 6]. PPARγ is primarily expressed in the
distal medullary collecting ducts, with lesser expression in
the glomeruli and renal microvasculature [7]. In the kidney,
PPARβ/δ is diﬀusely expressed in the renal cortex and2 PPAR Research
medulla, including medullary interstitial and stromal cells
[5]. This diﬀerential tissue distribution of the three PPAR
isoformsmayberelatedtotheirdistinctrolesinthesetissues,
including the kidney. Because the target genes of PPARα,-
β/δ,a n d- γ in these tissues are mainly involved in adipogene-
sis,lipidmetabolism,insulinsensitivity,glucosehomeostasis,
and cell growth and diﬀerentiation, PPARs could be the
target candidates that modulate body metabolisms.
Prior studies in animal models had described the beneﬁ-
cialrolesforPPARsinreducingrenalinjuryanddysfunction.
For instances, PPARβ/δ pretreatment could protect wild-
type mice from renal I/R injury, with a reduction in
medullary necrosis and inﬂammation [8]. PPARγ agonists
rosiglitazone and pioglitazone had shown protective eﬀects
against renal ischemia/reperfusion (I/R), diabetic nephropa-
thy, and various kidney injury [9, 10]. Although a role for
PPARα in reducing renal injury and PPARα ligands could
attenuate cisplatin-induced acute renal failure (ARF) was
reported in animal models [11, 12], its exact mechanisms are
still inconclusive. Therefore, this paper will focus on the role
of PPARα and its agonist in renal diseases.
3. PPARα LigandsandTheir
ClinicalImplications
Fibric acid derivatives or ﬁbrates are PPARα ligands. Fibrates
have been used in clinical practice for more than four
d e c a d e st od e c r e a s et r i g l y c e r i d el e v e l s .F i b r a t e sc a na l s o
increase HDL cholesterol levels, with a limited but signiﬁ-
cant additional eﬀect on decreasing low-density lipoprotein
(LDL) cholesterol levels. In addition to its major eﬀects
on lipid proﬁles, mounting evidence shows that beneﬁcial
eﬀects of ﬁbrates may be due to their anti-inﬂammatory and
antiatherosclerotic properties [13, 14]. The PPAR agonists
can be synthetic molecules, such as ﬁbrates used to treat
hypertriglyceridemia or thiazolidinediones to treat insulin
resistance, or natural ligands, such as fatty acids (FAs)
and their derivatives (eicosanoids). Although ﬁbrates are
most eﬃcient in patients with high TG and low HDL,
marginal eﬀects in the treatment of dyslipidemia were found
in the recent ACCORD (Action to Control Cardiovascular
Risk in Diabetes) trials to patients with type-2 diabetes
[15]. Nevertheless, recent ACCORD studies demonstrated
that ﬁbrate therapy with intensive glycemia control could
reduce renal microalbuminuria signiﬁcantly [16]. Although
microalbuminuria may rather be a marker for cardiovascular
disease [17], its applications as a reversible marker of kidney
and vascular damage were recently reported [18, 19].
4. PPARα andDiabeticN e p hr o path y
Although the abundance of PPARα in the kidney is
well established, its role in renal physiology and diabetic
nephropathy is just emerging. PPARα was implicated in the
regulation of kidney metabolism and to maintain a sustained
balance between energy production and expenditure [20],
given its high level expression in the renal proximal tubules
[5, 21, 22]. Cloﬁbrate activates PPARα and induces expres-
sion of β-oxidation enzymes, long-chain and medium-chain
acyl-CoA dehydrogenase, and acyl-CoA oxidase in the renal
cortex [23]. It is suggested that renal PPARα might play a
major role in triggering fatty acid utilization and adaptive
response to dietary lipids. This idea is further supported
by a recent study in which the beneﬁcial eﬀects of fasting-
induced upregulation of pyruvate dehydrogenase kinases
w e r eb l u n t e di nP P A R α-deﬁcient mice, indicating that loss
of PPARα can lead to abnormal renal regulation during
starvation [24]. Although PPARα induction is beneﬁcial in
fasting and hyperlipidemia, eﬀects of PPARα in diabetic
nephropathy remain unclear. However, clinical evidence
suggests a beneﬁcial eﬀect of ﬁbrate treatment in patients
with type-2 diabetes [25, 26], and data from the recent
FIELD (Fenoﬁbrate Intervention for Event Lowering in Dia-
betes) study also indicate promising eﬀects with fenoﬁbrate
in preventing progression of diabetes-related microvascular
complications [27]. In db/db type-2 diabetic mice, treatment
with fenoﬁbrate markedly lowers urinary albumin excretion
and improves glomerular mesangial expansion [28, 29].
Therefore, both clinical observations and rodent experi-
ments suggest that PPARα activation may play a beneﬁcial
role in diabetes induced nephropathy.
5. PPARα andKidneyMesangialCells
Cloﬁbrate has been shown to inhibit oxidative stress-
induced TGF-β expression in glomerular mesangial cells
[30]. Expression of PPARα in glomerular mesangial cells has
alsobeenreported[31];thusitislikelythatPPARαactivation
in mesangial cells could block TGF-β signaling pathway
and thereby attenuating glomerular matrix proliferation.
Consistent with this suggestion, a recent study demonstrated
that fenoﬁbrate downregulates TGF-β1a n dT G F - β signaling
receptor II expression and decreases collagen IV deposition
in the diabetic glomeruli [32]. Conversely, starved PPARα
null mice would show increased albuminuria with albumin
accumulation in the proximal tubules further conﬁrming the
beneﬁcial role of PPAR-α [33]. Therefore, it is likely that
PPARα activation may facilitate albumin reabsorption and
degradationinthenephronsegment[34,35].Takentogether,
fenoﬁbrate treatment activated PPARα may reduce TGF-
β-induced proliferation in mesangial cells, thus ameliorate
kidney injury.
6. Involvement of PPARα in Inﬂammation
PPARα plays a critical role as a primary sensor and regulator
of lipid metabolism, and this role has increasingly been rec-
ognized to be important in inﬂammation-induced disorders
including hypertension, metabolic disorders, cardiovascular
disease, atherosclerosis, and inﬂammation-induced acute
renal failure [36]. Fenoﬁbrates, ligands for PPARα,a r eu s e d
clinically to treat patients with type-2 diabetes or coronary
disease [37]. Fibrates can exert anti-inﬂammatory eﬀects,
by decreasing plasma levels of cytokines IL-6, TNFα,a n d
IFNγ in patients with atherosclerosis [38]o rl e v e lo fC R PPPAR Research 3
PPARα
PPARα
PPARα
PPARα
RXR
RXR
RXR
RXR
SUMO NCoR
NCoR Ligand
Ligand
CoAct
CoAct
Transcription of target gene
Renal epithelium cell apoptosis
Albuminuria
inﬂammation
ATP generation
Cisplatin &
I/R
DM
Glomerular
cells
PGI2
FAO↑
FFA↓
↑ATP
↓POx product
TGFβ↑
ROS↑
Masengial matrix proliferation↑
mesangial
NFκB-induced
IL-6↑, TNFα↑ and IFNγ↑
Figure 1: Schematic diagram presenting the signaling pathways of PPARα involved in the mechanisms of ischemic/reperfusion-, drugs-,
or diabetic-induced renal damage. PPARα forms heterodimer with RXR. In the absence of ligands, the dimer may recruit a corepressor,
inhibiting PPARα-mediated transcription of target genes. The presence of an agonist, or an activator such as PGI2, triggers the recruitment
of a coactivator complex which induces transcriptional activity of PPARα onto its target genes. This leads to an increase in fatty acid
catabolism and adenosine triphosphate (ATP) production, also to decrease the levels of cytotoxic fatty acid peroxidation (POx)p r o d u c t s ,
and, consequently, to promote cell viability and inhibit renal epithelium cell death. In addition, PPARα complex can attenuate NFκB-
induced inﬂammatory factors (IL-6, INFγ,o rT N F α) induced by ischemic/reperfusion injury (I/R) or drugs. Furthermore, PPARα complex
can inhibit masengial matrix proliferation induced by TGFβ or reactive oxidative stress (ROS) which then resulted in albuminuria. After
SUMOylationofPPARα,SUMOylat edPP ARαresultedindownregulationofitstranscriptionalactivitybypromotingitsinteractionwiththe
corepressor NCoR, which will compromise cell viability and activate cell death processes. CoAct, coactivator; DM, diabetes mellitus; FAO,
fatty acid oxidation; FFA, free fatty acid; IFNγ, interferon γ; IL-6, interleukine-6; I/R, ischemia/reperfusion; NCoR, nuclear corepressor;
NF-κB, nuclear factor-κB; PGI2, prostacyclin; POx, peroxidation; PPARα, peroxisome proliferator-activated receptor-α; RXR, retinoid X
receptor; TGFβ, tumor growth factor β;T N F α, tumor necrosis factor α.
in patients with cardiovascular diseases [39]. In human
endothelial cells, PPARα activators interfere with processes
involved in leukocyte recruitment and cell adhesion by
inhibiting the expression of VCAM-1. Since PPARα agonists
(fenoﬁbric acid and eicosapentaenoic acid) enhance e-
NOS expression and NO release, this suggests a vaso-
protective eﬀect. In other studies, synthetic PPARα activators
(fenoﬁbric acid and WY14643) diminish thrombin-induced
and oxidized LDL-induced expression of endothelin-1 [38].
PPARα activators can also modify inﬂammatory vascu-
lar smooth muscle cells (VSMC) activation by inhibiting
IL-1-induced production of IL-6 and prostaglandins and
by reducing the expression of cyclooxygenase-2 (COX-
2). In addition, PPARα agonists reduce tissue factor and
MMP expression in monocytes and macrophages. Moreover,
PPARα activation, in the presence of TNFα and IFNγ,m a y
promote macrophage apoptosis. Finally, activators of PPARα
limit the production of proatherogenic Th1 cytokines such
as IFNγ,T N F α, and IL-2 [38]. PPARα activators also inhibit
the inﬂammatory response in hepatocytes by decreasing
IL-1-induced CRP and IL-6-induced ﬁbrinogen α,- β,a n d
serum amyloid A expression [39]. PPARα thus acts as an
antiatherogenic factor by modulating local and systemic
inﬂammatory responses.
7. Involvement of PPARα in
Ischemia-Reperfusion-Induced
Kidney Injury
Although the causes of ARF are often multifactorial, they
can be generally classiﬁed into three categories depending
on the causes: (1) prerenal ARF, in which the kidney
fails to receive an adequate blood supply, for example,
due to a fall in systemic blood pressure subsequent to
hemorrhage [40]; (2) intrinsic ARF, in which the fail-
ure originates within the kidney, for example, due to
drug-induced nephrotoxicity like traditional cisplatin or4 PPAR Research
gentamicin-induced nephrotoxicity; and (3) postrenal ARF,
caused by impairment of urine ﬂow from the kidney, for
e x a m p l e ,d u et ou r e t e r a lo b s t r u c t i o no rb l a d d e r / p r o s t a t e
cancer. Increasing evidence supports a role for PPARα in
the development of ARF. Several studies have demonstrated
ar e d u c t i o ni nP P A R α expression, transcriptional activity,
and inhibition of peroxisomal and mitochondrial fatty acid
oxidation (FAO) enzymes in rodent renal tissue undergoing
cisplatin- and I/R-induced ARF [41]. Activation of PPARα
with ligands such as ﬁbrate or WY14643 reduces cisplatin
and I/R-induced acute kidney injury [42]. Importantly, these
eﬀects of ﬁbrate and WY14643 are not observed in PPARα-
null mice. These mice subjected to I/R injury by arterial
ligation show enhanced cortical necrosis and impaired renal
function [22]. However, such renal I/R injury could be
rescued via induction of PPARα with recovery of normal
kidney structure and function [22]. Recent investigations
using kidney androgen-induced protein 2 (KAP2) promoter
with tissue-restricted expression model further corroborate
the essential role of PPARα in renal protection [43]. As
KAP2 is exclusively expressed in the proximal tubules under
the control of androgens, their studies delineated that
the androgen-induced proximal tubules PPARα transgenic
mice could aﬀord protection against cisplatin- and I/R-
induced inhibition of FAO and protected kidney function
and morphology from these insults, in comparison with
their eﬀects on wild-type mice. In addition, the organ
and tissue (proximal tubule-) restricted expression model
in their studies further ruling out the potential PPARα-
independent, renoprotective actions as well as excluding
the potential PPARα-mediated, extrarenal eﬀects in renal
protection aﬀorded by PPARα activators in the PPARα-null
mouse [43]. We also demonstrated that prostacyclin may
act as an inducer, which can enhance PPARα translocation
into the nucleus and bind to inﬂammatory transcriptional
factor NFκB thus inhibiting TNFα-induced apoptosis in
renal epithelial cells. In addition, wild-type mice pretreated
with a PPARα activator, docosahexaenoic acid (DHA), could
signiﬁcantly reduce I/R-induced renal dysfunction (low-
ered serum creatinine and urea nitrogen levels), apoptotic
responses (decreased apoptotic cell number and caspase-3
and -8 activation), and NF-κBa c t i v a t i o n[ 33]. Altogether,
these studies strongly endorse a critical role of PPARα in
the preservation of renal morphology and function during
cisplatin- or I/R-induced acute renal damage.
8. Regulation of PPARα
Ligands binding to PPARα unmask an interaction area (of
PPARα) for coactivators such as cAMP response element-
binding protein (CREB-) binding protein (CBP)/p300. The
latter possesses histone acetyl transferase (HAT) activity
resulting in chromatin decondensation and PPARα het-
erodimerization with RXR. The binding of this heterodimer
to PPRE on PPARα promoter then regulates target genes
expression. In addition, PPARα(s) are substrates for several
kinases activated by a variety of endogenous or exoge-
nous signals. These kinase include: extracellular receptor
kinase-mitogen-activated protein kinase (ERK-MAPK), JNK
and p38 MAPK, Protein kinase A, Protein kinase C (PKC),
5 -AMP-activatedproteinkinase(AMPK),andglycogensyn-
thase kinase 3 (GSK3). Recently,SUMOylationof PPARαhas
reported that SUMOylated hPPARα on lysine 185 resulted in
down-regulation of its transcriptional activity by promoting
its interaction with the corepressor NCoR [44]. Therefore,
it is interesting to investigate whether PPARα modiﬁcation,
including phosporylation, SUMOylation, and ubiquitina-
tion, is involved in inﬂammation-induced renal failure.
Recently, we also demonstrated that adiponectin exerts
protectiveeﬀectagainstrenalischemic-reperfusioninjuryvia
prostacyclin- PPARα-heme oxygenase-1 signaling pathway
(unpublished data). A schematic diagram presenting the
regulation of PPARα in renal disease is depicted in Figure 1.
9. Conclusion andPerspectives
PPARα, in the last few years, has emerged as the key
regulator of lipid homeostasis in in vitro experiments and
clinical medicine. In addition, PPARα negatively regulates
inﬂammation-mediated phenomenon like atherosclerosis
and ARF. PPARα ligand and ﬁbrates are pharmacologic
agentswithpleiotropiceﬀects.Fibrateshavebeneﬁcialeﬀects
in alleviating cardiovascular abnormalities, ARF-, diabetic-
or drug-induced nephropathy, in both animal models and
clinical trials [45, 46]. Although the eﬀects of PPARα have
not been fully investigated, they are shown to be protective
in chronic kidney diseases.
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